2017
DOI: 10.1002/pbc.26750
|View full text |Cite
|
Sign up to set email alerts
|

Successful treatment of metastatic alveolar rhabdomyosarcoma with MGMT gene promoter methylation by temozolomide‐based combination chemotherapy

Abstract: A 3-year-old male presented with a large retroperitoneal mass and multiple metastases. Biopsy results suggested alveolar rhabdomyosarcoma bearing a methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter. Serum microRNA-206 levels were elevated and remained high after three cycles of vincristine, dactinomycin, and cyclophosphamide (VAC).Replacement of vincristine, irinotecan, and temozolomide (VIT) for VAC induced a marked tumor reduction and normalization of the miR-206 levels. The patient comp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(7 citation statements)
references
References 18 publications
0
7
0
Order By: Relevance
“…In total, 5 available case reports were found. We summarize the case reports in Table 1 ( 7 , 8 , 15 17 ). Of these cases, male children seem to be the more vulnerable group, which is consistent with overall incidence (male:female ratio of 1.51, 95% confidence interval (CI): 1.27–1.80) ( 18 ).…”
Section: Discussionmentioning
confidence: 99%
“…In total, 5 available case reports were found. We summarize the case reports in Table 1 ( 7 , 8 , 15 17 ). Of these cases, male children seem to be the more vulnerable group, which is consistent with overall incidence (male:female ratio of 1.51, 95% confidence interval (CI): 1.27–1.80) ( 18 ).…”
Section: Discussionmentioning
confidence: 99%
“…MGMT promoter methylation has been described in 13% to 43% of soft-tissue sarcomas such as undifferentiated pleomorphic sarcomas and liposarcomas (47,48). Clinically, application of temozolomide in MGMT-methylated sarcomas has only been described in case reports and a small case series (49)(50)(51). The first clinical study in patients with sarcoma is currently ongoing, evaluating MGMT status of patients with Ewing sarcoma receiving temozolomide and irinotecan (NCT03542097).…”
Section: Discussionmentioning
confidence: 99%
“…Another approach is the use of quantitative RT-PCR (qRT-PCR) to investigate the differential expression and/or release of miRNAs by solid tumors. 33 studies investigated miRNA in the serum or plasma of 2293 patients (miRNAs are listed Supplementary Table 2) [ [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , 44 , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] , [101] , [102] , [103] , [104] ]. In addition to qRT-PCR, one study used ddPCR [42] and three studies used TaqMan low density array (TLDA) [ 38 , 48 , 51 ].…”
Section: Detection Of Tumor-derived Cells and Nucleic Acid In Periphe...mentioning
confidence: 99%
“…The diagnostic value of one or more miRNAs were often evaluated by calculating area under the curve (AUC) at a predefined cutoff level of receiver operating characteristics (ROC) curves differentiating miRNA expression levels of patients and controls. Six studies used medical imaging including MRI, CT, and 18 F-FDG-PET/CT to determine tumor size, treatment response, and/or relapse [ 34 , 89 , 93 , 96 , 97 , 103 ].…”
Section: Detection Of Tumor-derived Cells and Nucleic Acid In Periphe...mentioning
confidence: 99%
See 1 more Smart Citation